Successes and failures for drugs in late-stage development for alzheimer's disease

Document Type

Article

Abstract

To date, symptomatic medications prevail as the mainstay of treatment options for Alzheimer's disease (AD). There have been tremendous investments made to increase the numbers of drugs approved and the targets engaged, in an effort to alter the disease course or pathophysiology of AD. Unfortunately, almost all studies have not met expectations and no new drug (beyond medical foods) has been approved for the treatment of AD in the last decade. This review is a comparison of novel AD therapies in the late phases of clinical testing, including recent high-profile clinical failures, and agents in development with relatively unexplored mechanisms of action, with a focus on their potential as therapeutic agents and their proposed advantages over the treatments currently in use. © 2013 Springer International Publishing Switzerland.

Publication Date

10-1-2013

Publication Title

Drugs and Aging

ISSN

1170229X

E-ISSN

11791969

Volume

30

Issue

10

First Page

783

Last Page

792

PubMed ID

23943247

Digital Object Identifier (DOI)

10.1007/s40266-013-0108-6

Link to Full Text

Share

COinS